13 news items
Zai Lab Has Dosed The First Patient In The Phase 2 Trial Of ZL-1102 For Chronic Plaque Psoriasis
ZLAB
22 May 24
capabilities
Based on a proof-of-concept study, ZL-1102 is the first topical biologic to show penetration of psoriatic skin resulting in a clinical response
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
ZLAB
22 May 24
of psoriatic skin resulting in a clinical response
Zai Lab Limited
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
ZLAB
20 May 24
patient cohort data confirm the findings of the global study regarding mortality and clinical response improvement
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
ZLAB
14 May 24
SC for the treatment of CIDP. Zai Lab enrolled patients into the ADHERE trial in Greater China and treatment response in these participants
Reported Sunday, Zai Lab Received Approval Of AUGTYRO (repotrectinib) For Patients With ROS1-Positive NSCLC By China's National Medical Products Administration
ZLAB
13 May 24
The approval is based on the pivotal TRIDENT-1 trial, in which AUGTYRO achieved a high response rate and durable responses, including robust intracranial responses
o9cngtgpus3s96un5xnlioms4r62d09zyx jij026iivgpn4axedi
ZLAB
12 May 24
trial, in which AUGTYRO achieved a high response rate and durable responses, including robust intracranial responses
l9gr7qefqsr66yk61ojlanpq9rzqv22vyfd9uwub004qvy tyszi
CRDF
JNJ
NTBL
9 May 24
between tumor responses and the expansion of tumor-infiltrating lymphocytes (TILs) in the blood, an effect that was observed in earlier pancreatic cancer
uo9j9lqux8umvufc5ow7 q6hwuztriqfwzkgbvpmpxn1f86ye8dahtawa
BMY
ZLAB
1 Apr 24
mutation.
The study met the primary endpoint of progression-free survival (PFS) and the key secondary endpoint of overall response rate (ORR
vfd1hgxiqbye7whcyxa63sx8x
NVCR
ZLAB
27 Mar 24
, overall survival, and radiological response rate) did not demonstrate statistical significance. Certain secondary endpoints showed positive trends
105br7w9ju28xtx92vmws97sg
NVCR
ZLAB
27 Mar 24
to neurocognitive failure, overall survival, and radiological response rate) did not demonstrate statistical significance. Certain secondary endpoints
52kixqgvrwjhno4mn0o6erz0ugwopiadqszao5rn3tpcyvkrl7ipu9in9z
ZLAB
6 Mar 24
each year. While platinum-based chemotherapy is effective at inducing an initial response in ovarian cancer, the disease will recur in the majority
wvec3tgr6onruj7xk5bgj50 a5dt3w9ml
ZLAB
6 Mar 24
chemotherapy is effective at inducing an initial response in ovarian cancer, the disease will recur in the majority of women. New agents that prolong
5zomj45z6id9z4hwdks
BILI
SDGR
ZH
25 Feb 24
leading venture capital firm Qiming Venture Partners announced its recent signing of the United Nations-supported Principles for Responsible Investment
- Prev
- 1
- Next